9 July 2018 - PHARMAC has announced the listing date and transition timeframes for a brand switch for entecavir from Baraclude to Entecavir Sandoz.

This follows a decision regarding the funding of entecavir and tenofovir disoproxil (as notified on 14 May 2018).

• The funded brand of entecavir will change from Baraclude (supplied by BMS) to Entecavir Sandoz (supplied by Novartis) as follows:
  
• A transition period will commence on 1 August 2018 when the new brand of entecavir (Entecavir Sandoz) is funded.
  
• Entecavir Sandoz will become the only funded brand of entecavir in both the community and hospital setting from 1 January 2019.
  
• A Brand Switch Fee will apply to tenofovir disoproxil and entecavir for three months from 1 January 2019.
  

Read PHARMAC press release